Home  |  Contact

UniProtKB/Swiss-Prot P10636: Variant p.Asn596Lys

Microtubule-associated protein tau
Gene: MAPT
Variant information

Variant position:  596
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Asparagine (N) to Lysine (K) at position 596 (N596K, p.Asn596Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (N) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In FTD; with parkinsonism.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  596
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  758
The length of the canonical sequence.

Location on the sequence:   KIGSTENLKHQPGGGKVQII  N KKLDLSNVQSKCGSKDNIKH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Gorilla                       KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Rhesus macaque                KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Chimpanzee                    KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Mouse                         KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Rat                           KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Bovine                        KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Goat                          KIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKH

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 758 Microtubule-associated protein tau
Repeat 592 – 622 Tau/MAP 2
Region 561 – 685 Microtubule-binding domain
Site 584 – 584 Not glycated
Site 591 – 591 Not glycated
Site 607 – 607 Not glycated
Site 611 – 611 Not glycated
Site 615 – 615 Not glycated
Modified residue 576 – 576 N6-acetyllysine; alternate
Modified residue 576 – 576 N6-methyllysine; alternate
Modified residue 579 – 579 Phosphoserine; by MARK1, MARK2, MARK3, MARK4, BRSK1, BRSK2 and PHK
Modified residue 596 – 596 Deamidated asparagine; in tau and PHF-tau; partial
Modified residue 598 – 598 N6-acetyllysine; alternate
Modified residue 602 – 602 Phosphoserine; by PHK
Modified residue 607 – 607 N6-acetyllysine
Modified residue 610 – 610 Phosphoserine
Modified residue 615 – 615 N6-acetyllysine; alternate
Glycosylation 576 – 576 N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Glycosylation 597 – 597 N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Glycosylation 598 – 598 N-linked (Glc) (glycation) lysine; in PHF-tau; in vitro
Cross 576 – 576 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Cross 584 – 584 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Cross 598 – 598 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Cross 615 – 615 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin); alternate
Alternative sequence 592 – 622 Missing. In isoform Tau-A, isoform Tau-B, isoform Tau-C and isoform Fetal-tau.
Mutagenesis 579 – 579 S -> A. 8% decrease in microtubule-binding after in vitro phosphorylation of mutant protein.
Beta strand 592 – 596


Literature citations

Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.
Clark L.N.; Poorkaj P.; Wszolek Z.; Geschwind D.H.; Nasreddine Z.S.; Miller B.; Li D.; Payami H.; Awert F.; Markopoulou K.; Andreadis A.; D'Souza I.; Lee V.M.-Y.; Reed L.; Trojanowski J.Q.; Zhukareva V.; Bird T.; Schellenberg G.; Wilhelmsen K.C.;
Proc. Natl. Acad. Sci. U.S.A. 95:13103-13107(1998)
Cited for: VARIANTS FTD LYS-596 AND LEU-618;

A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy.
Delisle M.-B.; Murrell J.R.; Richardson R.; Trofatter J.A.; Rascol O.; Soulages X.; Mohr M.; Calvas P.; Ghetti B.;
Acta Neuropathol. 98:62-77(1999)
Cited for: VARIANT PPND LYS-596;

A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration.
Yasuda M.; Kawamata T.; Komure O.; Kuno S.; D'Souza I.; Poorkaj P.; Kawai J.; Tanimukai S.; Yamamoto Y.; Hasegawa H.; Sasahara M.; Hazama F.; Schellenberg G.D.; Tanaka C.;
Neurology 53:864-868(1999)
Cited for: VARIANT FTD LYS-596;

Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene.
Arima K.; Kowalska A.; Hasegawa M.; Mukoyama M.; Watanabe R.; Kawai M.; Takahashi K.; Iwatsubo T.; Tabira T.; Sunohara N.;
Neurology 54:1787-1795(2000)
Cited for: VARIANT FTD LYS-596;

Clinical and genetic studies of families with the tau N279K mutation (FTDP-17).
Tsuboi Y.; Baker M.; Hutton M.L.; Uitti R.J.; Rascol O.; Delisle M.-B.; Soulages X.; Murrell J.R.; Ghetti B.; Yasuda M.; Komure O.; Kuno S.; Arima K.; Sunohara N.; Kobayashi T.; Mizuno Y.; Wszolek Z.K.;
Neurology 59:1791-1793(2002)
Cited for: VARIANT FTD LYS-596;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.